Skip to menu Skip to content Skip to footer
Associate Professor David Wyld
Associate Professor

David Wyld

Email: 

Overview

Availability

Associate Professor David Wyld is:
Available for supervision

Works

Search Professor David Wyld’s works on UQ eSpace

214 works between 1998 and 2025

181 - 200 of 214 works

2012

Conference Publication

Usefulness of medical oncologists' estimates of survival time in people with advanced cancer

Kiely, Belinda E., Martin, Andrew J., Tattersall, Martin H. N., Nowak, Anna K., Goldstein, David, Wilcken, Nicholas, Wyld, David, Beale, Philip James, Jefford, Michael, Glasgow, Amanda L., Abdi, Ehtesham A., Glare, Paul A. and Stockler, Martin R. (2012). Usefulness of medical oncologists' estimates of survival time in people with advanced cancer. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 1-6 June 2012. Alexandria, VA USA: American Society of Clinical Oncology.

Usefulness of medical oncologists' estimates of survival time in people with advanced cancer

2012

Conference Publication

Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancer

Dzienis, M., Malczewski, A., Goh, J., Hughes, B., Eastgate, M., Wyld, D. and Burge, M. (2012). Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancer. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting, Brisbane, QLD Australia, 8-10 August 2012. Wiley-Blackwell Publishing.

Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancer

2012

Journal Article

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

Chirgwin, Jacquie, Sun, Zhuoxin, Smith, Ian, Price, Karen N., Thuerlimann, Beat, Ejlertsen, Bent, Bonnefoi, Herve, Regan, Meredith M., Goldhirsch, Aron, Coates, Alan S., International Breast Cancer Study Group (IBCSG) and Wyld, David (2012). The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Research and Treatment, 131 (1), 295-306. doi: 10.1007/s10549-011-1741-6

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

2012

Conference Publication

Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k

Shapiro, Jeremy David, Siu, Lillian L., O'Callaghan. Christopher J., Zalcberg, John Raymond, Moore, Malcolm J., Price, Timothy Jay, Doyle, Catherine, Simes, John, Findlay, Brian Peter, Cronk, Michelle F., Shaikh, Asif, Joubert, Warren Lance, Samson, Benoit, Bonaventura, Antonino, Underhill, Craig, Wyld, David, Walters, Ian B., Phillips, Penny, Tu, Dongsheng and Jonker, Derek J. (2012). Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k. 2012 ASCO Annual Meeting, Chicago Il, United States, 01-05 June 2012. Alexandria, VA United States: American Society of Clinical Oncology.

Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k

2012

Conference Publication

Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's Hospital

Sharma, A., Burge, M., MacFarlane, D., McDade, H., Kemp, S. and Wyld, D. (2012). Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's Hospital. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting , Brisbane, QLD, Australia, 8 – 10 August 2012. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing.

Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's Hospital

2011

Journal Article

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Pavel, Marianne E., Hainsworth, John D., Baudin, Eric, Peeters, Marc, Hörsch, Dieter, Winkler, Robert E., Klimovsky, Judith, Lebwohl, David, Jehl, Valentine, Wolin, Edward M., Öberg, Kjell, Van Cutsem, Eric, Yao, James C., RADIANT-2 Study Group and Wyld, D. (2011). Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. The Lancet, 378 (9808), 2005-2012. doi: 10.1016/S0140-6736(11)61742-X

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

2011

Journal Article

Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot study

Newton, Melissa J ., Hayes, Sandi C., Janda, Monika, Webb, Penelope M., Obermair, Andreas, Eakin, Elizabeth G., Wyld, David, Gordon, Louisa G. and Beesley, Vanessa L. (2011). Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot study. BMC Cancer, 11 (1) 389, 389-1-389-9. doi: 10.1186/1471-2407-11-389

Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot study

2011

Journal Article

Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

Regan, Meredith M, Price, Karen N, Giobbie-Hurder, Anita, Thürlimann, Beat, Gelber, Richard D, International Breast Cancer Study Group and BIG 1-98 Collaborative Group, Colosimo, M., Cheuk, R., Kenny, L., McCarthy, N. and Wyld, D. (2011). Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast cancer research : BCR, 13 (3) 209, 209. doi: 10.1186/bcr2837

Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

2011

Journal Article

Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma

Obermair, Andreas, Mileshkin, Linda, Bolz, Katharina, Kondalsamy-Chennakesavan, Srinivas, Cheuk, Robyn, Vasey, Paul, Wyld, David, Goh, Jeffrey, Nicklin, James L., Perrin, Lewis C., Sykes, Peter and Janda, Monika (2011). Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. Gynecologic Oncology, 120 (2), 179-184. doi: 10.1016/j.ygyno.2010.10.039

Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma

2011

Conference Publication

Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective study

Burge, M., Houston, K. E., Francesconi, A., O'Rourke, N., Lee, J., Macfarlane, D., Wyld, D., Hopkins, G., Finch, R. and Nathanson, L. (2011). Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective study. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011. Elsevier: Oxford, United Kingdom.

Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective study

2010

Journal Article

Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients

Beesley, Vanessa L., Clavarino, Alexandra M., Webb, Penelope M., Wyld, David K., Francesconi, Alessandra B., Horwood, Keith R., Doecke, James D., Loos, Colleen A. and Green, Adele C. (2010). Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients. Supportive Care in Cancer, 18 (8), 943-949. doi: 10.1007/s00520-009-0734-z

Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients

2010

Journal Article

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent

Lickliter, J. D., Francesconi, A. B., Smith, G., Burge, M., Coulthard, A., Rose, S., Griffin, M., Milne, R., McCarron, J., Yeadon, T., Wilks, A., Cubitt, A., Wyld, D. K. and Vasey, P. A. (2010). Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. British Journal of Cancer, 103 (5), 597-606. doi: 10.1038/sj.bjc.6605841

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent

2010

Journal Article

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study

Tebbutt, Niall C., Wilson, Kate, Gebski, Val J., Cummins, Michelle M., Zannino, Diana, Van Hazel, Guy A., Robinson, Bridget, Broad, Adam, Ganju, Vinod, Ackland, Stephen P., Forgeson, Garry, Cunningham, David, Saunders, Mark P., Stockler, Martin R., Chua, Yujo, Zalcberg, John R., Simes, R. John, Price, Timothy J., Price, Tim, Simes, John, Coates, Alan, O'Connell, Diane, Brown, Chris, Hague, Wendy, France, Alyson, Hicks, Sian, James, Rebecca, Masson, Ruby, O'Connell, Rachel ... Gebbie, Chantal (2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. Journal of Clinical Oncology, 28 (19), 3191-3198. doi: 10.1200/JCO.2009.27.7723

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study

2010

Journal Article

Medical costs and outcomes for Australian women with ovarian cancer: A patient-level analysis over 2.5 years

Gordon, Louisa G., Scuffham, Paul A., Beesley, Vanessa L., Green, Adele C., DeFazio, Anna, Wyld, David K., Clavarino, Alexandra M., Australian Ovarian Cancer Study Group and Webb, Penelope M. (2010). Medical costs and outcomes for Australian women with ovarian cancer: A patient-level analysis over 2.5 years. International Journal of Gynecological Cancer, 20 (5), 757-765. doi: 10.1111/IGC.0b013e3181dbd13f

Medical costs and outcomes for Australian women with ovarian cancer: A patient-level analysis over 2.5 years

2010

Journal Article

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

Francesconi, Alessandra B., Dupre, Simon, Matos, Marco, Martin, David, Hughes, Brett G., Wyld, David K. and Lickliter, Jason D. (2010). Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. Journal of Clinical Neuroscience, 17 (8), 970-974. doi: 10.1016/j.jocn.2009.12.009

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

2009

Journal Article

Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers

Herbertson, Rebecca A., Tebbutt, Niall C., Lee, Fook-Thean, MacFarlane, David J., Chappell, Bridget, Micallef, Noel, Lee, Sze-Ting, Saunder, Timothy, Hopkins, Wendie, Smyth, Fiona E., Wyld, David K., Bellen, John, Sonnichsen, Daryl S., Brechbiel, Martin W., Murone, Carmel and Scott, Andrew M. (2009). Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clinical Cancer Research, 15 (21), 6709-6715. doi: 10.1158/1078-0432.CCR-09-0536

Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers

2009

Journal Article

Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial

Au, Heather-Jane, Karapetis, Christos S., O'Callaghan, Chris J., Tu, Dongsheng, Moore, Malcolm J., Zalcberg, John R., Kennecke, Hagen, Shapiro, Jeremy D., Koski, Sheryl, Pavlakis, Nick, Charpentier, Danielle, Wyld, David, Jefford, Michael, Knight, Gregory J., Magoski, Nadine M., Brundage, Michael D. and Jonker, Derek J. (2009). Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology, 27 (11), 1822-1828. doi: 10.1200/JCO.2008.19.6048

Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial

2009

Journal Article

Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis

Francesconi, Alessandra Bastian, Matos, Marco, Lee, Joseph C., Wyld, David K., Clouston, Andrew D. and Macfarlane, David (2009). Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis. Annals of Nuclear Medicine, 23 (5), 497-499. doi: 10.1007/s12149-009-0252-6

Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis

2008

Conference Publication

Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer

Lickliter, J., Francesconi, A., Smith, G., Burge, M., Coulthard, A., Rose, S., Griffin, M., Wilks, A., Wyld, D. and Vasey, P. (2008). Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer. 2008 ASCO Annual Meeting, Chicago, IL, U.S.A., 30 May - 3 June, 2008. Alexandria, VA. U.S.A.: American Society of Clinical Oncology.

Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer

2007

Journal Article

Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial

Stockler, M. R., O'Connell, R., Nowak, A. K., Goldstein, D., Turner, J., Wilcken, N. R. C., Wyld, D., Abdi, E., Glasgow, A., Beale, P. J., Jefford, M., Dhillon, H., Heritier, S., Carter, C., Hickie, I. B. and Simes, R. J. (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. The Lancet Oncology, 8 (7), 603-612. doi: 10.1016/S1470-2045(07)70148-1

Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial

Funding

Current funding

  • 2020 - 2026
    A new radio-imaging agent to guide targeted therapy for epithelial ovarian cancer
    NHMRC MRFF EPCDR - Ovarian Cancer Research
    Open grant

Past funding

  • 2020 - 2025
    PRoCESS: Pancreatic cancer Relatives Counselling and Education Support Service trial....(MRFF RCRDUN administered by QMIR)
    Queensland Institute of Medical Research
    Open grant

Supervision

Availability

Associate Professor David Wyld is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

For media enquiries about Associate Professor David Wyld's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au